Screener
Zevra Therapeutics, Inc. ZVRA Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfDebt.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:14 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001434647-26-000031
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Sales and maturities of investments | 93,972 | 18,000 |
| Net cash provided by investing activities | 79,618 | 10,542 |
| Cash flows from financing activities: | ||
| Repayment of debt | (60,092) | — |
| Payments for employee taxes related to stock awards | (2,635) | |
| Proceeds from issuance of common stock for options exercised | 752 | 1,979 |
| Proceeds from issuance of common stock for warrants exercised | 9,171 | — |
| Payments of principal on insurance financing arrangements | — | (372) |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s debt repayments?
- Zevra Therapeutics, Inc. (ZVRA) reported debt repayments of $60.09M in Q1 2026.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Zevra Therapeutics, Inc.'s debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude